Gene · 259197
Papers4,252
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 4,252
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Phenotypes, mechanisms, and therapeutic strategies of natural killer cell immunosenescence. | Immun Ageing | 2025 | 41121385 | PubTator, text mining | PubMed |
| Combined IFN-γ and TNF-α treatment enhances the susceptibility of breast cancer cells and spheroids to Natural Killer cell-mediated killing. | Cell Death Dis | 2025 | 41102150 | PubTator, text mining | PubMed |
| NKp30 and NKG2D contribute to natural killer cell-mediated recognition of HIV-infected cells. | iScience | 2025 | 41079618 | PubTator, text mining | PubMed |
| Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells. | Sci Rep | 2025 | 41053108 | PubTator, text mining | PubMed |
| Phenotypic and epigenetic profiles of circulating NK cells in spontaneous HIV-1 controllers. | EBioMedicine | 2025 | 41027310 | PubTator, text mining | PubMed |
| Tertiary Lymphoid Structures Across Organs: Context, Composition, and Clinical Levers. | Immunol Rev | 2025 | 40996881 | PubTator, text mining | PubMed |
| IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy. | Oncoimmunology | 2025 | 40996786 | PubTator, text mining | PubMed |
| Advancing our understanding of the influence of myeloid-derived suppressor cells in chronic myeloid leukemia. | J Cancer Res Clin Oncol | 2025 | 40970984 | PubTator, text mining | PubMed |
| Nanoscale restructuring of the immune synapse with an engager enhances NK cell function. | Proc Natl Acad Sci U S A | 2025 | 40966288 | PubTator, text mining | PubMed |
| Research Progress of Natural Killer Cells in Hashimoto's Thyroiditis. | Immunotargets Ther | 2025 | 40964505 | PubTator, text mining | PubMed |
| MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment. | J Immunother Cancer | 2025 | 40954074 | PubTator, text mining | PubMed |
| Helixor A enhances natural killer cell activity by induction of PAI-1 expression through the p38/MAPK signaling pathway. | Int Immunopharmacol | 2025 | 40945034 | PubTator, text mining | PubMed |
| Comprehensive Characterisation of Extracellular Vesicle Preparations Using Multiparametric Size-Exclusion Chromatography. | Int J Mol Sci | 2025 | 40943398 | PubTator, text mining | PubMed |
| CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. | Int J Mol Sci | 2025 | 40943160 | PubTator, text mining | PubMed |
| Mechanisms Underlying Treatment-Resistant Depression: Exploring Sex-Based Biological Differences. | J Neurochem | 2025 | 40903897 | PubTator, text mining | PubMed |
| Evaluating the causal effect of circulating proteome on the risk of Juvenile idiopathic arthritis: an omics pipeline study. | Pediatr Rheumatol Online J | 2025 | 40898345 | PubTator, text mining | PubMed |
| Toggling of NKG2A expression drives functional specialization of iPSC-derived CAR NK cells. | bioRxiv | 2025 | 40894717 | PubTator, text mining | PubMed |
| Optimizing colloidal stability and viscosity of multispecific antibodies at the drug discovery-development interface: a systematic predictive case study. | MAbs | 2025 | 40888155 | PubTator, text mining | PubMed |
| Targeting immunosenescence and inflammaging: advancing longevity research. | Exp Mol Med | 2025 | 40887496 | PubTator, text mining | PubMed |
| Inhibiting the DNA damage repair of HNSCC cells in combination with normo-fractionated radiotherapy influences clonogenicity, senescence and expression of NK cell activation markers. | Sci Rep | 2025 | 40883442 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/259197/papers?page=5